A major step forward
The Botswana Medicines Regulatory Authority (BoMRA) has successfully concluded a five-day assisted self-benchmarking exercise with the support of the World Health Organisation (WHO).
The assessment, conducted using the WHO Global Benchmarking Tool (GBT), reviewed all regulatory functions to guide BoMRA’s journey toward achieving Maturity Level 3 (ML3), the global standard for an integrated, fully functional pharmaceutical regulatory system.
Why does this matter for Botswana?
Attaining WHO ML3 will be a critical milestone for the nation, guaranteeing even greater safety, quality, and effectiveness of medicines for everyone in Botswana.
Speaking during the closing session, BoMRA CEO Dr. Seima Dijeng expressed gratitude to the WHO experts and the BoMRA team for their collaborative effort towards the journey to ML3.
He emphasised the importance of understanding the the status of the country’s regulatory system and addressing identified gaps and areas of improvement. He further commended the dedicated BoMRA team for their commitment and hard work, ensuring that the public has timely access to trusted medical products.
The assessment signalled a positive outcome, indicating that the attainment of ML3 is on the horizon, a remarkable milestone for a regulatory authority that commenced operations only six years ago, in 2018.
The assessors highlighted key strengths, including political will and Government support, strong technical capacity and BoMRA’s active participation in regional and global regulatory forums.
Key areas for improvement were also identified, such as strengthening financial resources, legal framework and staffing levels to enable BoMRA to execute regulatory mandates more effectively.
This progress reinforces BoMRA’s strategic priorities to align its regulatory framework with global health standards in order to safeguard public health.
The journey to ML3 and beyond continues.







